Peter Bross

2.2k total citations · 2 hit papers
14 papers, 1.4k citations indexed

About

Peter Bross is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Peter Bross has authored 14 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 4 papers in Hematology and 3 papers in Molecular Biology. Recurrent topics in Peter Bross's work include CAR-T cell therapy research (3 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Bladder and Urothelial Cancer Treatments (2 papers). Peter Bross is often cited by papers focused on CAR-T cell therapy research (3 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Bladder and Urothelial Cancer Treatments (2 papers). Peter Bross collaborates with scholars based in United States and Thailand. Peter Bross's co-authors include Richard Pazdur, Robert C. Kane, Ann T. Farrell, Atiqur Rahman, Gang Chen, Grant Williams, Eamon Duffy, Sandip Kumar Roy, R N Sridhara and Julie Beitz and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and The American Journal of Gastroenterology.

In The Last Decade

Peter Bross

12 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.

2001 660 citations Peter Bross, Julie Beitz et al. PubMed profile →
Velcade®: U.S. FDA Approval for the Treatment of Multiple Myeloma Progressing on Prior Therapy

2003 505 citations Robert C. Kane, Peter Bross et al. The Oncologist profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Bross United States	8	686	600	464	279	159	14	1.4k
Joanna Opalinska United States	19	1.2k 1.7×	589 1.0×	776 1.7×	245 0.9×	161 1.0×	52	1.9k
Mingjie Li United States	19	583 0.8×	624 1.0×	682 1.5×	315 1.1×	276 1.7×	94	1.4k
Michaël Sébag Canada	23	1.0k 1.5×	766 1.3×	801 1.7×	255 0.9×	187 1.2×	115	1.8k
Antonia Cagnetta Italy	13	607 0.9×	612 1.0×	597 1.3×	219 0.8×	168 1.1×	38	1.2k
Pascale Lejeune Germany	16	876 1.3×	522 0.9×	287 0.6×	276 1.0×	149 0.9×	44	1.6k
Phuong L. Doan United States	21	624 0.9×	258 0.4×	564 1.2×	160 0.6×	288 1.8×	57	1.4k
Benno Rattel Germany	17	452 0.7×	804 1.3×	257 0.6×	469 1.7×	459 2.9×	36	1.3k
Michele S. Redell United States	18	562 0.8×	402 0.7×	315 0.7×	48 0.2×	203 1.3×	50	1.1k
Iris Breitkreutz United States	14	879 1.3×	697 1.2×	1.0k 2.2×	113 0.4×	204 1.3×	34	1.5k
W. E. Berdel Germany	19	546 0.8×	445 0.7×	383 0.8×	50 0.2×	240 1.5×	49	1.3k

Countries citing papers authored by Peter Bross

Since Specialization

Citations

This map shows the geographic impact of Peter Bross's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Bross with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Bross more than expected).

Fields of papers citing papers by Peter Bross

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Bross. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Bross. The network helps show where Peter Bross may publish in the future.

Co-authorship network of co-authors of Peter Bross

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Bross. A scholar is included among the top collaborators of Peter Bross based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Bross. Peter Bross is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Bross, Peter, Karin M. Knudson, Million A. Tegenge, et al.. (2025). FDA Approval Summary: Lifileucel for Unresectable or Metastatic Melanoma Previously Treated with an Anti–PD-1–Based Immunotherapy. Clinical Cancer Research. 31(19). 4004–4009. 1 indexed citations

Jia, Yuqian, Alpana Sharma, Daniel L. Suzman, et al.. (2024). FDA Approval Summary: Nadofaragene Firadenovec-vncg for Bacillus Calmette–Guérin–Unresponsive Non–Muscle-Invasive Bladder Cancer. Clinical Cancer Research. 31(7). 1182–1185. 8 indexed citations

Bross, Peter, et al.. (2023). S4176 Cocaine-Induced Gastric Ulcers: An Under-Recognized Disease. The American Journal of Gastroenterology. 118(10S). S2642–S2642.

Bross, Peter, et al.. (2019). Expanded access for cancer patients: The 5-year FDA CBER experience.. Journal of Clinical Oncology. 37(15_suppl). e18158–e18158.

Bross, Peter, et al.. (2014). Regulation of biologic oncology products in the FDA׳s Center for Biologics Evaluation and Research. Urologic Oncology Seminars and Original Investigations. 33(3). 133–136. 4 indexed citations

Bross, Peter, Ke Liu, Marc R. Theoret, et al.. (2013). Regulation of immunotherapeutic products for cancer and FDA’s role in product development and clinical evaluation. Journal for ImmunoTherapy of Cancer. 1(1). 5–5. 17 indexed citations

Hinman, Lois M., Brian B. Spear, Zenta Tsuchihashi, et al.. (2008). Drug–Diagnostic Codevelopment Strategies: FDA and Industry Dialog at the 4th FDA/DIA/PhRMA/PWG/BIO Pharmacogenomics Workshop. Pharmacogenomics. 10(1). 127–136. 12 indexed citations

Bross, Peter, Gang Chen, Richard T. Lostritto, et al.. (2003). Fulvestrant in postmenopausal women with advanced breast cancer.. PubMed. 9(12). 4309–17. 46 indexed citations

Johnson, John R., Peter Bross, Martin H. Cohen, et al.. (2003). Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.. PubMed. 9(6). 1972–9. 83 indexed citations

10.

Johnson, John R., Peter Bross, Martin H. Cohen, et al.. (2003). Report from the FDA Approval Summary: Imatinib Mesylate Capsules for Treatment of Adult Patients with Newly Diagnosed Philadelphia Chromosome- positive Chronic Myelogenous Leukemia in Chronic Phase. 1 indexed citations

11.

Kane, Robert C., Peter Bross, Ann T. Farrell, & Richard Pazdur. (2003). Velcade®: U.S. FDA Approval for the Treatment of Multiple Myeloma Progressing on Prior Therapy. The Oncologist. 8(6). 508–513. 505 indexed citations breakdown →

12.

Bross, Peter, Martin H. Cohen, Grant A. Williams, & Richard Pazdur. (2002). FDA Drug Approval Summaries: Fulvestrant. The Oncologist. 7(6). 477–480. 62 indexed citations

13.

Bross, Peter, Julie Beitz, Gang Chen, et al.. (2001). Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.. PubMed. 7(6). 1490–6. 660 indexed citations breakdown →

14.

Bross, Peter, et al.. (1999). Empiric antimicrobial therapy of febrile neutropenic patients undergoing haematopoietic stem cell transplantation. International Journal of Antimicrobial Agents. 13(2). 127–130. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact